Des-gamma-carboxy prothrombin
EstablishedDCP is a complementary liver cancer marker used alongside AFP within composite scoring systems like GALAD.
DCP is another blood marker for liver cancer, used alongside AFP rather than by itself. Combining several markers together (like in the GALAD score) works better than relying on just one.
Des-gamma-carboxy prothrombin (DCP), also called PIVKA-II, is an abnormal form of prothrombin produced by liver cancer cells due to impaired vitamin K-dependent carboxylation, serving as a complementary biomarker to AFP in hepatocellular carcinoma.
Elevated DCP supports hepatocellular carcinoma diagnosis, particularly in combination with AFP and AFP-L3%, since no single marker alone offers adequate sensitivity for early-stage detection.
DCP is one of three components (with AFP and AFP-L3%) of the GALAD score for hepatocellular carcinoma detection; the FDA has approved DCP and AFP-L3% as risk-stratification tools that may be complementary to AFP, though neither is currently approved for standalone HCC surveillance in the United States due to insufficient sensitivity for early-stage detection.
DCP does not function as a useful standalone marker in current guidelines; it is used within composite scoring systems like GALAD to improve on AFP's detection accuracy for early-stage liver cancer.
FDA-approved as a risk-stratification aid, but not currently approved for standalone HCC surveillance.
- EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma. (2024). Journal of Hepatology.
- Radiology. (2024). LI-RADS US Surveillance Version 2024.